145 related articles for article (PubMed ID: 34397109)
1. Hyperhaemolytic transfusion reaction in two β-thalassaemia major patients: The role of eculizumab.
Pantelidou D; Pilalas D; Daios S; Polychronopoulos G; Papadopoulou D; Perifanis V; Savopoulos C; Kaiafa G
J Clin Pharm Ther; 2022 Mar; 47(3):411-414. PubMed ID: 34397109
[TBL] [Abstract][Full Text] [Related]
2. Hyperhaemolysis caused by anti-HI antibodies in a patient with myelodysplastic syndrome following a first ever red cell transfusion.
Hinton R; Haji R; Kaczmarski R; Layton M; Danga A
Transfus Med; 2023 Aug; 33(4):349-351. PubMed ID: 37186414
[TBL] [Abstract][Full Text] [Related]
3. Successful Management of Severe Hyperhaemolysis with Combined Tocilizumab and Rituximab in Non-Transfusion-Dependent Thalassaemia: A Case Report.
El Afifi AM; Saeed AM; Fekry GH; Mostafa MA; Elmetwally RA; Hamed IM; Hussein AN; Hasanien GM
Transfus Med Hemother; 2023 Feb; 50(1):66-70. PubMed ID: 36818772
[TBL] [Abstract][Full Text] [Related]
4. Post-transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction.
Cullis JO; Win N; Dudley JM; Kaye T
Vox Sang; 1995; 69(4):355-7. PubMed ID: 8751307
[TBL] [Abstract][Full Text] [Related]
5. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.
Vlachaki E; Gavriilaki E; Kafantari K; Adamidou D; Tsitsikas D; Chasapopoulou E; Anagnostopoulos A; Tsapas A
Hemoglobin; 2018; 42(5-6):339-341. PubMed ID: 30626228
[TBL] [Abstract][Full Text] [Related]
6. Delayed Severe Hemolytic Transfusion Reaction During Pregnancy in a Woman with β-Thalassemia Intermediate: Successful Outcome After Eculizumab Administration.
Cannas G; Dubreuil L; Fichez A; Gerfaud-Valentin M; Debard AL; Hot A
Am J Case Rep; 2021 May; 22():e931107. PubMed ID: 33983909
[TBL] [Abstract][Full Text] [Related]
7. Management of Hyperhemolysis in β-thalassemia With Multiple Immunosuppressives, Including Complement Blockade.
Zanetti RC; Vasta LM; Romanelli K; Newton TC
J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1145-e1147. PubMed ID: 33480648
[TBL] [Abstract][Full Text] [Related]
8. Hyperhaemolytic Syndrome in Sickle Cell Disease: Clearing the Cobwebs.
Madu AJ; Ugwu AO; Efobi C
Med Princ Pract; 2021; 30(3):236-243. PubMed ID: 33176303
[TBL] [Abstract][Full Text] [Related]
9. Anti-N and anti-Do
Unnikrishnan A; Pelletier JPR; Bari S; Zumberg M; Shahmohamadi A; Spiess BD; Michael MJ; Harris N; Harrell D; Mandernach MW
Transfusion; 2019 Jun; 59(6):1907-1910. PubMed ID: 30768787
[TBL] [Abstract][Full Text] [Related]
10. Refractory hyperhaemolysis in a patient with beta-thalassaemia major.
Grainger JD; Makar Y; McManus A; Wynn R
Transfus Med; 2001 Feb; 11(1):55-7. PubMed ID: 11328573
[TBL] [Abstract][Full Text] [Related]
11. A case of hyperhaemolysis syndrome in a pregnant Chinese woman with β-thalassemia during perinatal transfusion.
Wu Y; Ji Y; Dai B; Guo F; Wu Y; He Z; Mo C; Wu S; Hu Y
Transfus Med; 2021 Feb; 31(1):24-29. PubMed ID: 33331032
[TBL] [Abstract][Full Text] [Related]
12. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab.
Gupta S; Fenves A; Nance ST; Sykes DB; Dzik WS
Transfusion; 2015 Mar; 55(3):623-8. PubMed ID: 25257194
[TBL] [Abstract][Full Text] [Related]
13. Eculizumab for management of hyperhemolysis syndrome in pediatric patients with sickle cell disease: A single-center case series.
Lapite A; Bhar S; Fasipe T
Pediatr Blood Cancer; 2024 Aug; 71(8):e31061. PubMed ID: 38840429
[TBL] [Abstract][Full Text] [Related]
14. [Severe hemolysis related to an association of erythrocyte allo- and autoantibodies in a thalassemia patients].
Mizon P; Cossement C; Mannessier L; Caulier MT; Rose C; Goudemand J
Transfus Clin Biol; 1996; 3(4):257-61. PubMed ID: 8983518
[TBL] [Abstract][Full Text] [Related]
15. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria.
Schubert J; Hillmen P; Röth A; Young NS; Elebute MO; Szer J; Gianfaldoni G; Socié G; Browne P; Geller R; Rother RP; Muus P;
Br J Haematol; 2008 Jun; 142(2):263-72. PubMed ID: 18503589
[TBL] [Abstract][Full Text] [Related]
16. A single dose of eculizumab terminated life-threatening haemolysis in idiopathic IgM-mediated warm autoimmune haemolytic anaemia: A case report.
Garg M; Agarwal S; Altohami M
Br J Haematol; 2022 Apr; 197(2):e28-e31. PubMed ID: 34993954
[No Abstract] [Full Text] [Related]
17. Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review.
Jacobs JW; Stephens LD; Allen ES; Binns TC; Booth GS; Hendrickson JE; Karafin MS; Tormey CA; Woo JS; Adkins BD
Br J Haematol; 2023 Jun; 201(6):1025-1032. PubMed ID: 37074146
[TBL] [Abstract][Full Text] [Related]
18. Hyperhaemolysis syndrome in a patient with myelofibrosis.
Treleaven JG; Win N
Hematology; 2004 Apr; 9(2):147-9. PubMed ID: 15203871
[TBL] [Abstract][Full Text] [Related]
19. Treatment of post-transfusion hyperhaemolysis syndrome in Sickle Cell Disease with the anti-IL6R humanised monoclonal antibody Tocilizumab.
Sivapalaratnam S; Linpower L; Sirigireddy B; Agapidou A; Jain S; Win N; Tsitsikas DA
Br J Haematol; 2019 Sep; 186(6):e212-e214. PubMed ID: 31368112
[No Abstract] [Full Text] [Related]
20. Salvage of refractory post-transfusion hyperhaemolysis by targeting hyperinflammation and macrophage activation with tocilizumab.
Chen F; Booth C; Barroso F; Bennett S; Kaya B; Win N; Telfer P
Transfus Med; 2022 Oct; 32(5):437-440. PubMed ID: 34046955
[No Abstract] [Full Text] [Related]
[Next] [New Search]
